Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (Annals of Hematology, (2020), 99, 8, (1793-1804), 10.1007/s00277-020-04149-5)

Martin Kaiser; Meral Beksaç; Nina Gulbrandsen; Fredrik Schjesvold; Roman Hájek; Philippe Moreau; Felipe de Arriba de la Fuente; María Victoria Mateos; Sharon West; Andrew Spencer; S. Vincent Rajkumar; Kaveri Suryanarayan; Michael Czorniak; Cong Li; Zhaoyang Teng; Richard Labotka; Meletios A. Dimopoulos

doi:10.1007/s00277-020-04302-0

Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (Annals of Hematology, (2020), 99, 8, (1793-1804), 10.1007/s00277-020-04149-5)

Martin Kaiser, Meral Beksaç, Nina Gulbrandsen, Fredrik Schjesvold, Roman Hájek, Philippe Moreau, Felipe de Arriba de la Fuente, María Victoria Mateos, Sharon West, Andrew Spencer, S. Vincent Rajkumar, Kaveri Suryanarayan, Michael Czorniak, Cong Li, Zhaoyang Teng, Richard Labotka, Meletios A. Dimopoulos

Hematology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Low-resolution figures were inadvertently created during production and published. These have been replaced with the high-resolution figures that were originally provided by the authors. No changes have been made to the data presented within the figures or to any other manuscript content.Please see below for the high-resolution figures:.

Original language	English (US)
Pages (from-to)	297-302
Number of pages	6
Journal	Annals of hematology
Volume	100
Issue number	1
DOIs	https://doi.org/10.1007/s00277-020-04302-0
State	Published - Jan 2021

ASJC Scopus subject areas

Hematology

Access to Document

10.1007/s00277-020-04302-0

Fingerprint

Dive into the research topics of 'Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (Annals of Hematology, (2020), 99, 8, (1793-1804), 10.1007/s00277-020-04149-5)'. Together they form a unique fingerprint.

Cite this

Kaiser, M., Beksaç, M., Gulbrandsen, N., Schjesvold, F., Hájek, R., Moreau, P., de la Fuente, F. D. A., Mateos, M. V., West, S., Spencer, A., Rajkumar, S. V., Suryanarayan, K., Czorniak, M., Li, C., Teng, Z., Labotka, R., & Dimopoulos, M. A. (2021). Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (Annals of Hematology, (2020), 99, 8, (1793-1804), 10.1007/s00277-020-04149-5). Annals of hematology, 100(1), 297-302. https://doi.org/10.1007/s00277-020-04302-0

Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (Annals of Hematology, (2020), 99, 8, (1793-1804), 10.1007/s00277-020-04149-5). / Kaiser, Martin; Beksaç, Meral; Gulbrandsen, Nina et al.
In: Annals of hematology, Vol. 100, No. 1, 01.2021, p. 297-302.

Research output: Contribution to journal › Comment/debate › peer-review

Kaiser, M, Beksaç, M, Gulbrandsen, N, Schjesvold, F, Hájek, R, Moreau, P, de la Fuente, FDA, Mateos, MV, West, S, Spencer, A, Rajkumar, SV, Suryanarayan, K, Czorniak, M, Li, C, Teng, Z, Labotka, R & Dimopoulos, MA 2021, 'Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (Annals of Hematology, (2020), 99, 8, (1793-1804), 10.1007/s00277-020-04149-5)', Annals of hematology, vol. 100, no. 1, pp. 297-302. https://doi.org/10.1007/s00277-020-04302-0

@article{25efcd77dc074357b02f37d7a27ff984,

title = "Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (Annals of Hematology, (2020), 99, 8, (1793-1804), 10.1007/s00277-020-04149-5)",

abstract = "Low-resolution figures were inadvertently created during production and published. These have been replaced with the high-resolution figures that were originally provided by the authors. No changes have been made to the data presented within the figures or to any other manuscript content.Please see below for the high-resolution figures:.",

author = "Martin Kaiser and Meral Beksa{\c c} and Nina Gulbrandsen and Fredrik Schjesvold and Roman H{\'a}jek and Philippe Moreau and {de la Fuente}, {Felipe de Arriba} and Mateos, {Mar{\'i}a Victoria} and Sharon West and Andrew Spencer and Rajkumar, {S. Vincent} and Kaveri Suryanarayan and Michael Czorniak and Cong Li and Zhaoyang Teng and Richard Labotka and Dimopoulos, {Meletios A.}",

note = "Publisher Copyright: {\textcopyright} 2020, Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2021",

month = jan,

doi = "10.1007/s00277-020-04302-0",

language = "English (US)",

volume = "100",

pages = "297--302",

journal = "Annals of hematology",

issn = "0939-5555",

publisher = "Springer Verlag",

number = "1",

}

TY - JOUR

T1 - Correction to

T2 - Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (Annals of Hematology, (2020), 99, 8, (1793-1804), 10.1007/s00277-020-04149-5)

AU - Kaiser, Martin

AU - Beksaç, Meral

AU - Gulbrandsen, Nina

AU - Schjesvold, Fredrik

AU - Hájek, Roman

AU - Moreau, Philippe

AU - de la Fuente, Felipe de Arriba

AU - Mateos, María Victoria

AU - West, Sharon

AU - Spencer, Andrew

AU - Rajkumar, S. Vincent

AU - Suryanarayan, Kaveri

AU - Czorniak, Michael

AU - Li, Cong

AU - Teng, Zhaoyang

AU - Labotka, Richard

AU - Dimopoulos, Meletios A.

PY - 2021/1

Y1 - 2021/1

N2 - Low-resolution figures were inadvertently created during production and published. These have been replaced with the high-resolution figures that were originally provided by the authors. No changes have been made to the data presented within the figures or to any other manuscript content.Please see below for the high-resolution figures:.

AB - Low-resolution figures were inadvertently created during production and published. These have been replaced with the high-resolution figures that were originally provided by the authors. No changes have been made to the data presented within the figures or to any other manuscript content.Please see below for the high-resolution figures:.

UR - http://www.scopus.com/inward/record.url?scp=85093826581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85093826581&partnerID=8YFLogxK

U2 - 10.1007/s00277-020-04302-0

DO - 10.1007/s00277-020-04302-0

M3 - Comment/debate

C2 - 33106909

AN - SCOPUS:85093826581

SN - 0939-5555

VL - 100

SP - 297

EP - 302

JO - Annals of hematology

JF - Annals of hematology

IS - 1

ER -

Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (Annals of Hematology, (2020), 99, 8, (1793-1804), 10.1007/s00277-020-04149-5)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this